Role of PPARα and its agonist in renal diseases

PPAR Research

Volumn , Issue , 2010, Pages

  Lin, Heng ^a   Cheng, Ching Feng ^a,b   Chen, Hsi Hsien ^c  

^a TZU CHI UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CLOFIBRATE; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOCOSAHEXAENOIC ACID; FENOFIBRATE; GAMMA INTERFERON; GENTAMICIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PROTEIN KINASE C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DYSLIPIDEMIA; ENZYME ACTIVATION; HUMAN; INFLAMMATION; KIDNEY INJURY; KIDNEY METABOLISM; LIGAND BINDING; LIPID PEROXIDATION; MESANGIUM CELL; METABOLIC SYNDROME X; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; UBIQUITINATION;

EID: 78650796942     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2010/345098     Document Type: Review

References (46)

1. Berger J. P., Akiyama T. E., Meinke P. T., PPARs: therapeutic targets for metabolic disease Trends in Pharmacological Sciences 2005 26 5 244 251
2. Fruchart J. C., Staels B., Duriez P., The role of fibric acids in atherosclerosis Current Atherosclerosis Reports 2001 3 1 83 92
3. Fajas L., Debril M.-B., Auwerx J., Peroxisome proliferator-activated receptor- : from adipogenesis to carcinogenesis Journal of Molecular Endocrinology 2001 27 1 1 9 (Pubitemid 32771453)
4. Mukherjee R., Jow L., Noonan D., McDonnell D. P., Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators Journal of Steroid Biochemistry and Molecular Biology 1994 51 3-4 157 166
5. Guan Y., Zhang Y., Davis L., Breyer M. D., Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans American Journal of Physiology 1997 273 6, part 2 F1013 F1022
6. Ruan X. Z., Moorhead J. F., Fernando R., Wheeler D. C., Powis S. H., Varghese Z., PPAR agonists protect mesangial cells from interleukin 1 -induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway Journal of the American Society of Nephrology 2003 14 3 593 600
7. Guan Y., Zhang Y., Schneider A., Davis L., Breyer R. M., Breyer M. D., Peroxisome proliferator-activated receptor- activity is associated with renal microvasculature American Journal of Physiology 2001 281 6 F1036 F1046
8. Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J.-P., Heudes D., Wahli W., Desvergne B., Baud L., Peroxisome proliferator-activated receptor / exerts a strong protection from ischemic acute renal failure Journal of the American Society of Nephrology 2005 16 8 2395 2402
9. Chung B. H., Lim S. W., Ahn K. O., Sugawara A., Ito S., Choi B. S., Kim Y. S., Bang B. K., Yang C. W., Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases Nephrology 2005 10 supplement 2 S40 S43
10. Cuzzocrea S., Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury Vascular Pharmacology 2004 41 6 187 195
11. Portilla D., Dai G., Peters J. M., Gonzalez F. J., Crew M. D., Proia A. D., Etomoxir-induced PPAR -modulated enzymes protect during acute renal failure American Journal of Physiology 2000 278 4 F667 F675
12. Li S., Bhatt R., Megyesi J., Gokden N., Shah S. V., Portilla D., PPAR- ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G American Journal of Physiology 2004 287 5 F990 F998
13. Staels B., Fruchart J.-C., Therapeutic roles of peroxisome proliferator-activated receptor agonists Diabetes 2005 54 8 2460 2470 (Pubitemid 41134276)
14. Israelian-Konaraki Z., Reaven P. D., Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications Cardiology 2005 103 1 1 9 (Pubitemid 39541239)
15. Wierzbicki A. S., Fibrates: no ACCORD on their use in the treatment of dyslipidaemia Current Opinion in Lipidology 2010 21 4 352 358
16. Ismail-Beigi F., Craven T., Banerji M. A., Basile J., Calles J., Cohen R. M., Cuddihy R., Cushman W. C., Genuth S., Grimm Jr. R. H., Hamilton B. P., Hoogwerf B., Karl D., Katz L., Krikorian A., O'Connor P., Pop-Busui R., Schubart U., Simmons D., Taylor H., Thomas A., Weiss D., Hramiak I., Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial The Lancet 2010 376 9739 419 430
17. de Zeeuw D., Parving H.-H., Henning R. H., Microalbuminuria as an early marker for cardiovascular disease Journal of the American Society of Nephrology 2006 17 8 2100 2105 (Pubitemid 44141898)
18. Czekalski S., Microalbuminuria as a reversible marker of kidney and vascular damage Nefrologia i Dializoterapia Polska 2006 10 4 166 168
19. Cerasola G., Cottone S., Mul G., The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. Journal of Hypertension. In press
20. Portilla D., Energy metabolism and cytotoxicity Seminars in Nephrology 2003 23 5 432 438
21. Beck F., Plummer S., Senior P. V., Byrne S., Green S., Brammar W. J., The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat Proceedings of the Royal Society B 1992 247 1319 83 87
22. Portilla D., Dai G., Peters J. M., Gonzalez F. J., Crew M. D., Proia A. D., Etomoxir-induced PPAR -modulated enzymes protect during acute renal failure American Journal of Physiology 2000 278 4 F667 F675
23. Ouali F., Djouadi F., Merlet-Bnichou C., Bastin J., Dietary lipids regulate -oxidation enzyme gene expression in the developing rat kidney American Journal of Physiology 1998 275 5 F777 F784
24. Sugden M. C., Bulmer K., Gibbons G. F., Holness M. J., Role of peroxisome proliferator-activated receptor- in the mechanism underlying changes in renal pyruvate dehydrogenase kinase isoform 4 protein expression in starvation and after refeeding Archives of Biochemistry and Biophysics 2001 395 2 246 252
25. Fried L. F., Orchard T. J., Kasiske B. L., Effect of lipid reduction on the progression of renal disease: a meta-analysis Kidney International 2001 59 1 260 269
26. Smolders Y. M., van Eeden A. E., Stehouwer C. D. A., Weijers R. N. M., Slaats E. H., Silberbusch J., Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? European Journal of Clinical Investigation 1997 27 12 997 1002
27. Keech A., Simes R. J., Barter P., Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial The Lancet 2005 366 9500 1849 1861
28. Park C. W., Zhang Y., Fan X. F., A PPAR agonist improves diabetic nephropathy in db/db mice Journal of the American Society of Nephrology 2003 14 393A
29. Park C. W., Zhang Y., Zhang X., Wu J., Chen L., Cha D. R., Su D., Hwang M.-T., Fan X., Davis L., Striker G., Zheng F., Breyer M., Guan Y., PPAR agonist fenofibrate improves diabetic nephropathy in db/db mic Kidney International 2006 69 9 1511 1517
30. Wilmer W. A., Dixon C. L., Hebert C., Lu L., Rovin B. H., PPAR- ligands inhibit H2O2 -mediated activation of transforming growth factor- 1 in human mesangial cells Antioxidants Redox Signaling 2002 4 6 877 884
31. Hou X., Shen Y. H., Li C., Wang F., Zhang C., Bu P., Zhang Y., PPAR agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity Biochemical and Biophysical Research Communications 2010 394 3 653 659
32. Li L., Emmett N., Mann D., Zhao X., Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor- B and transforming growth factor- 1/Smad3 in diabetic nephropathy Experimental Biology and Medicine 2010 235 3 383 391
33. Chen H.-H., Chen T.-W., Lin H., Prostacyclin-induced peroxisome proliferator-activated receptor- translocation attenuates NF- B and TNF- activation after renal ischemia-reperfusion injury American Journal of Physiology 2009 297 4 F1109 F1118
34. Liao J., Soltani Z., Ebenezer P., Isidro-Carrin A. A., Zhang R., Asghar A., Aguilar E., Francis J., Hu X., Ferder L., Reisin E., Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR / ), improves metabolic abnormalities and reduces renal injury in obese Zucker rats Nephron Experimental Nephrology 2009 114 2 e61 e68
35. Calkin A. C., Giunti S., Jandeleit-Dahm K. A., Allen T. J., Cooper M. E., Thomas M. C., PPAR- and- agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse Nephrology Dialysis Transplantation 2006 21 9 2399 2405
36. Robinson E., Grieve D. J., Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease Pharmacology Therapeutics 2009 122 3 246 263
37. Seiler C., Suter T. M., Hess O. M., Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate Journal of the American College of Cardiology 1995 26 7 1615 1622
38. Gilde A. J., van der Lee K. A.J.M., Willemsen P. H.M., Chinetti G., Van der Leij F. R., Van der Vusse G. J., Staels B., Van Bilsen M., Peroxisome proliferator-activated receptor (PPAR) and PPAR /, but not PPAR, modulate the expression of genes involved in cardiac lipid metabolism Circulation Research 2003 92 5 518 524
39. Zambon A., Gervois P., Pauletto P., Fruchart J.-C., Staels B., Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR- activators: clinical and experimental evidence Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 5 977 986
40. Thadhani R., Pascual M., Bonventre J. V., Acute renal failure The New England Journal of Medicine 1996 334 22 1448 1460
41. Lopez-Hernandez F. J., Lopez-Novoa J. M., Potential utility of PPAR activation in the prevention of ischemic and drug-induced acute renal damage Kidney International 2009 76 10 1022 1024
42. Sivarajah A., Chatterjee P. K., Hattori Y., Brown P. A. J., Stewart K. N., Todorovic Z., Mota-Filipe H., Thiemermann C., Agonists of peroxisome-proliferator activated receptor- (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat Medical Science Monitor 2002 8 12 BR532 BR539
43. Li S., Nagothu K. K., Desai V., Lee T., Branham W., Moland C., Megyesi J. K., Crew M. D., Portilla D., Transgenic expression of proximal tubule peroxisome proliferator-activated receptor- in mice confers protection during acute kidney injury Kidney International 2009 76 10 1049 1062
44. Pourcet B., Pineda-Torra I., Derudas B., Staels B., Glineur C., SUMOylation of human peroxisome proliferator-activated receptor inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR Journal of Biological Chemistry 2010 285 9 5983 5992
45. Dogra G., Irish A., Chan D., Watts G., A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD American Journal of Kidney Diseases 2007 49 6 776 785
46. Sica D. A., Fibrate therapy and renal function Current Atherosclerosis Reports 2009 11 5 338 342